Experimental Peptide Guide · Reviewed August 16, 2026
TB-500: Human Evidence, FDA Status, and Safety
TB-500 is commonly discussed alongside full-length thymosin beta-4, but they are not interchangeable evidence targets. This guide keeps the marketed fragment, the broader Tβ4 literature, and current FDA status separate.
Unapproved-drug notice
TB-500 is not an FDA-approved drug product. Advisory-committee review, an RUO label, online sale, or a compounded preparation does not establish FDA approval, clinical effectiveness, product quality, or suitability for human use [2,3,5].
Affiliate disclosure
Some pages may include affiliate links. If you buy through those links, The Hippie Scientist may earn a commission at no additional cost to you. Affiliate relationships do not change evidence ratings, safety warnings, product-quality criteria, or editorial conclusions.
Read our affiliate and editorial policyTB-500 vs. Thymosin Beta-4
Full-length thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid peptide with a substantial preclinical research literature. FDA's current compounding safety page identifies TB-500 as the thymosin beta-4 fragment LKKTETQ. Evidence for full-length Tβ4 should not be silently presented as human efficacy or safety evidence for the TB-500 fragment [1,4].
What the Evidence Can Show
| Evidence target | What exists | What it supports | What it does not support |
|---|---|---|---|
| Full-length Tβ4 | Broad preclinical and translational literature [4] | Biologic hypotheses involving migration, repair, angiogenesis, and injury models | Direct efficacy or safety of the TB-500 fragment |
| TB-500 fragment | Much thinner molecule-specific evidence | A reason to study the fragment separately | A validated human treatment effect |
| Human exposure | FDA says it has not identified human exposure data for drug products containing the fragment [1] | Evidence that a major safety-information gap remains | A human dose, adverse-event rate, or long-term safety profile |
| Wound healing | FDA reviewed TB-500-related substances for this proposed use at the July 2026 PCAC meeting [2] | Regulatory/scientific review of the nomination | FDA approval or established efficacy |
| Sports recovery | No robust controlled human outcome program identified for marketed fragment use | Uncertainty | Claims that TB-500 reliably accelerates tendon, ligament, or muscle recovery |
Evidence quality: preliminary and molecule-sensitive. Parent-peptide biology is not proof for the marketed fragment.
FDA & Compounding Status — checked August 16, 2026
FDA's Pharmacy Compounding Advisory Committee reviewed TB-500 free base and TB-500 acetate on July 23, 2026 for the nominated use of wound healing [2]. FDA also states that advisory committees make non-binding recommendations. Committee consideration therefore should not be translated into FDA approval or a final 503A-list action.
| Statement | Status | Why |
|---|---|---|
| TB-500 is FDA-approved | No | No approved TB-500 drug product is established by the cited FDA record [1-3] |
| PCAC reviewed TB-500-related substances | Yes | July 23, 2026 meeting; wound healing was the evaluated use [2] |
| PCAC activity equals a final 503A rule | No | FDA describes 503A-list decisions as a separate agency rulemaking process [2,3] |
| Compounded TB-500 would be FDA-approved | No | Compounded drugs are not FDA-approved before marketing [5] |
| RUO / online availability proves lawful clinical use | No | Availability is not an approval, efficacy, quality, or legal-status determination |
Safety Uncertainty
- FDA flags potential immunogenicity for certain routes because of aggregation and peptide-related impurity concerns [1].
- FDA says it has not identified human exposure data for drug products containing the TB-500 fragment and lacks important information about whether it would cause harm in humans [1].
- Safety findings from full-length Tβ4 cannot automatically be transferred to a different fragment, formulation, dose, or route.
- Injectable compounded or gray-market products add identity, sterility, contamination, strength, and handling risks that efficacy studies do not resolve [5].
Bottom Line
TB-500 is often marketed using the scientific credibility of full-length thymosin beta-4, but the fragment has a much thinner direct human evidence trail. The July 2026 FDA advisory review did not make it an approved therapy, and FDA's current safety page still emphasizes missing human exposure and safety information [1,2].
Source ledger
References
5 sources
- 01FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current TB-500 / thymosin beta-4 fragment safety entry. Source →
- 02FDA. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. TB-500 free base / acetate were evaluated for wound healing. Source →
- 03FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Current bulks-list framework and rulemaking process. Source →
- 04Goldstein AL, et al. Thymosin beta-4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012. PMID 22500833. Review concerns full-length thymosin beta-4, not direct human efficacy of marketed TB-500 fragment products. PubMed →
- 05FDA. Understanding the Risks of Compounded Drugs. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. Source →